全球多发性硬化症治疗市场 – 行业趋势和 2031 年预测

多发性硬化症治疗市场分析和规模

在多发性硬化症 (MS) 治疗市场，正在进行的研究重点是多种治疗方法。干细胞疗法旨在修复受损神经并促进髓鞘再生，具有治疗潜力。奥瑞珠单抗等 B 细胞耗竭疗法针对与 MS 进展有关的特定免疫细胞，降低复发率。芬戈莫德等小分子药物可调节免疫反应，以减轻 MS 患者的炎症。这些创新反映了向个性化医疗的转变，即根据个体疾病情况量身定制治疗方案，提高疗效，同时最大限度地减少副作用。不断发展的形势凸显出一系列新型疗法，这些疗法有望推动 MS 管理并改善全球患者的治疗效果。

2023 年全球多发性硬化症治疗市场规模价值 259.5 亿美元，预计到 2031 年将达到 336.5 亿美元，2024 年至 2031 年预测期内的复合年增长率为 3.30%。

除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Multiple sclerosis (MS) treatment aims to manage symptoms, slow disease progression, and improve quality of life for patients. Treatments include disease-modifying therapies (DMTs) that can reduce relapses and delay disability progression by modulating the immune response. Symptomatic treatments target specific symptoms such as muscle spasms, fatigue, and cognitive issues. Rehabilitation therapies, lifestyle modifications, and supportive care also play crucial roles in managing MS symptoms and enhancing overall well-being. Treatment plans are personalized based on the type of MS, disease progression, and individual patient needs.

Multiple Sclerosis Treatment Market Dynamics

Drivers                                                                                          

• Increasing Prevalence of Multiple Sclerosis

Multiple sclerosis is becoming more prevalent due to various factors including improved diagnostic capabilities, heightened awareness leading to more frequent and earlier diagnosis, and changing environmental and lifestyle factors. As the number of MS cases rises, there is a growing demand for effective disease-modifying therapies (DMTs) that can manage symptoms, slow disease progression, and improve quality of life. This trend not only fuels pharmaceutical research and development efforts to innovate new treatments but also drives healthcare investments in infrastructure and supportive care services tailored to MS patients. Moreover, rising prevalence underscores the importance of expanding access to treatments across different healthcare settings to meet the increasing demand globally.

• Rising Technological Advancements in Healthcare

Advanced imaging techniques such as magnetic resonance imaging (MRI) provide detailed insights into disease activity and progression, aiding in early diagnosis and treatment planning. Telemedicine and digital health platforms enable remote monitoring of MS patients, facilitating timely interventions and personalized care approaches. Furthermore, innovations in drug delivery systems, including improved infusion devices and novel formulations, enhance treatment adherence and patient convenience. Alongside traditional pharmaceutical treatments, technological advancements support the development and integration of alternative treatments for multiple sclerosis, such as complementary therapies and lifestyle interventions, expanding the scope of options available to patients and healthcare providers.

Opportunities

• Expansion of Government Initiatives

Governments worldwide allocate funding for MS research, supporting the development of innovative disease-modifying therapies (DMTs) and symptomatic treatments. Regulatory agencies provide approvals and incentives for new treatments, expediting their availability to patients. Additionally, public health programs and policies focus on early detection, diagnosis, and management of MS, which reduces disease burden and improves patient outcomes. Government initiatives also include advocacy for patient rights, ensuring equitable access to healthcare services and treatments, thus stimulating market growth and innovation in MS treatment strategies.

• Growing Patient Awareness

Increased awareness among patients about the importance of early diagnosis, available treatment options, and the benefits of proactive disease management leads to higher demand for effective therapies. Patients are more such asly to seek medical help earlier, leading to timely initiation of disease-modifying therapies (DMTs) that can slow progression and improve outcomes. Moreover, informed patients are better equipped to participate in treatment decisions and adhere to prescribed therapies, enhancing overall treatment efficacy. This awareness also fuels advocacy efforts, influencing healthcare policies and funding for MS research, ultimately contributing to advancements in treatment options and improved quality of life for MS patients globally.

Restraints/Challenges

• High Cost of Therapies

Disease-modifying therapies (DMTs), which are the primary treatments for MS, often come with substantial price tags that can pose financial burdens on patients, healthcare systems, and insurers. These costs limit accessibility, particularly in regions with lower healthcare budgets or where insurance coverage is inadequate. Patients may face challenges in affording continuous treatment, leading to gaps in therapy adherence and potentially compromising disease management outcomes. Moreover, the high costs deter investment in research and development for more affordable treatment options, perpetuating the cycle of limited accessibility and innovation in MS care.

• Growing Safety Concerns

Many disease-modifying therapies (DMTs) for MS can cause adverse effects ranging from mild to severe, including flu-such assymptoms, injection site reactions, gastrointestinal issues, and more serious risks such as immune suppression or liver toxicity. These side effects can lead to treatment discontinuation or reluctance to initiate therapy, limiting the effectiveness of MS management. Furthermore, the variability in individual patient responses to DMTs complicates treatment decisions, necessitating careful monitoring and personalized approaches.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In October 2023, Bristol Myers Squibb presented data on Zeposia (ozanimod) showing that 76% of patients with relapsing multiple sclerosis (RMS) treated with Zeposia were free of six-month confirmed disability progression (CDP), highlighting its effectiveness in long-term disease progression and cognition
• In September 2023, Sandoz received European Commission (EC) marketing authorization for biosimilar Tyruko (natalizumab) for multiple sclerosis. This follows the U.S. FDA approval in August 2023, indicating a significant regulatory milestone for this biosimilar treatment.
• In August 2021, Novartis launched Kesimpta (ofatumumab) in the U.S. after FDA approval, marking it as the first self-administered, targeted B-cell therapy for relapsing multiple sclerosis (RMS). Kesimpta offers potent efficacy and an acceptable safety profile, addressing a critical need by allowing home administration

Multiple Sclerosis Treatment Market Scope

The market is segmented on the basis of type, drug class, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Clinically isolated syndrome (CIS)
• Relapse-remitting MS (RRMS)
• Primary progressive MS (PPMS)
• Secondary progressive MS (SPMS)

Treatment

• Medications
• Stem Cell Therapy
• Physical Therapy
• Plasma Exchange
• Others

Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons
• Others

Diagnosis

• Magnetic Resonance Imaging (MRI)
• Simple Electrical Stimulation Tests
• Lumbar Puncture
• Others

Route of Administration

• Oral
• Parenteral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Multiple Sclerosis Treatment Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by type, drug class, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.   

North America dominates the market due to increased expenditure on research and development, advancements in R&D capabilities, growing government initiatives supporting healthcare innovation, and improved healthcare infrastructure across the region. These elements collectively contribute to North America's ability to lead in developing and adopting advanced treatments for multiple sclerosis, ensuring continued growth and leadership in the forecast period.

Asia-Pacific is expected to experience significant growth in the market due to increased government expenditure on healthcare, rising adoption of advanced technologies in medical treatments, and various governmental initiatives aimed at improving healthcare infrastructure and accessibility. The region's expanding healthcare sector is poised to support the development and availability of innovative MS treatments, meeting the growing demand from a rising number of diagnosed patients. These developments indicate a promising outlook for MS treatment advancements and accessibility across Asia-Pacific in the coming years.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和多发性硬化症治疗市场分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对表观遗传学诊断市场的关注有关。

市场上的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd（瑞士）
• 雅培（美国）
• 西门子（德国）
• 丹纳赫（美国）
• 生物梅里埃公司（法国）
• Ortho Clinical Diagnostics（美国）
• Randox Laboratories Ltd（英国）
• BG 医药（美国）
• HUMAN 公司（德国）
• Bhat Bio-tech India Private Limited（印度）
• 默克集团（德国）
• PerkinElmer Inc.（美国）
• QIAGEN（荷兰）
• 安捷伦科技公司（美国）
• 布鲁克 (美国)
• Epigenomics AG（德国）
• MESO SCALE DIAGNOSTICS, LLC（美国）
• EKF Diagnostics Holdings plc.（英国）
• Nexus-Dx（美国）
• LifeSign LLC.（美国）
• DIALAB GmbH（奥地利）
• 贝克曼库尔特公司（美国）

SKU-26312